TORONTO, May 11 /CNW/ - Patheon (TSX: PTI) announced today the
appointment of Michael E. Lytton as Patheon's Executive Vice President,
Corporate Development and Strategy and General Counsel, effective
immediately. Mr. Lytton was most recently with Biogen Idec, Inc.,
where he held the position of Executive Vice President, Corporate and
Business Development reporting to Jim Mullen, previously Chief
Executive Officer of Biogen Idec and now Patheon's Chief Executive
In commenting on the appointment, Mr. Mullen said, "I am so pleased that
Michael has agreed to join us. He is an accomplished leader,
strategist and negotiator who will bring a deep and broad understanding
of the industry and proven skills to help Patheon reach its full
potential. I expect that Michael will assist us in building strategic
alliances with our pharmaceutical and biotechnology customers as well
as emerging companies and their investors, and that he will enable us
to add a range of proprietary capabilities and technologies to better
serve our customers."
Mr. Lytton's 28-year career includes extensive experience in the
pharmaceutical and biotech industry. Most recently, Mr. Lytton
supported Biogen Idec's growth by leading its corporate development
team that refined and executed its corporate partnership strategy,
including the in-licensing of several late-stage molecules. Prior to
joining Biogen Idec, Mr. Lytton was a General Partner with Oxford
Bioscience Partners, a venture capital firm investing in therapeutic,
diagnostic, and life science tool companies. Prior to Oxford, Mr.
Lytton practiced law for 17 years and specialized in representing
biomedical companies; he is a past Partner and member of the Executive
Committee of the law firm Edwards Angell Palmer & Dodge and previously
was a Partner of the law firm Wilmer Hale.
Mr. Lytton is currently Chairman of the Board of Santhera
Pharmaceuticals AG and he has also served on various boards of many
other academic, non-profit and private and public for-profit companies
throughout his career.
Mr. Lytton holds an undergraduate degree from Princeton University, a Master of Science degree in
Epidemiology from the London School of Hygiene and Tropical Medicine at
the University of London, U.K. where he was a Fulbright Scholar, and a
Juris Doctor from Harvard Law School.
Patheon is a leading global provider of contract development and
manufacturing services to the global pharmaceutical industry. It
provides the highest quality products and services to approximately 300
of the world's leading pharmaceutical and biotechnology companies.
Patheon's services range from preclinical development through
commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi‐solid and liquid forms. The company uses many
innovative technologies including single‐use disposables, liquid‐filled
hard capsules and a variety of modified release technologies. Its
comprehensive range of fully integrated Pharmaceutical Development
Services includes pre‐formulation, formulation, analytical development,
clinical manufacturing, scale‐up and commercialization. Patheon can
take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic™ programs can
accelerate early phase development projects to clinical trials while
minimizing the consumption of valuable API. Its integrated development
and manufacturing network of 10 facilities, eight development centers
and one clinical trial packaging facility, across North America and
Europe, ensures that customer products can be launched on‐time and with
confidence anywhere in the world.
SOURCE Patheon Inc.
For further information:
Investor Relations and Corporate Communications
Tel: (919) 226-3313